Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (Nasdaq: DTIL) filed this Current Report on Form 8-K on December 4, 2020. The filing serves as a Regulation FD disclosure to announce positive interim clinical results from its Phase 1/2a study of PBCAR0191, an off-the-shelf allogeneic CAR T cell therapy targeting CD19. The report also covers the completion of preclinical work for PBCAR19B, a CD19 "Stealth Cell" candidate.
Key Financial Metrics
This filing is a current report regarding clinical developments and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing details significant clinical progress as of the November 16, 2020 cutoff, involving 27 patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) and R/R B-cell acute lymphoblastic leukemia (B-ALL).
- Enhanced Lymphodepletion (eLD) Results: Patients receiving PBCAR0191 with eLD achieved an 83% objective response rate (ORR). Specifically, 75% of NHL patients (3/4) achieved a complete response (CR).
- Standard Lymphodepletion (sLD) Results: Across dose levels DL2 and DL3, 33% of NHL patients (n=9) achieved a CR.
- Durability: The longest demonstrated response was greater than 11 months in a B-ALL patient at dose level DL2.
- Cell Expansion: PBCAR0191 demonstrated a clear dose-dependent increase in peak cell expansion. Compared to sLD, eLD at DL3 resulted in approximately a 95-fold increase in peak cell expansion.
- Safety Profile: The therapy showed an acceptable safety profile with no cases of graft versus host disease, no Grade 3 or higher cytokine release syndrome, and no Grade 3 or higher immune effector cell neurotoxicity.
Guidance, Outlook, and Risks
Outlook: The Company plans to enroll additional patients using the eLD regimen and intends to present longer-term follow-up data by mid-2021. Clinical trials for the PBCAR19B "Stealth Cell" candidate are expected to commence in 2021.
Risks and Contingencies: One NHL patient treated with PBCAR0191 and eLD died at day 42 due to Grade 5 sepsis. This patient had a complex history, including nine prior lines of therapy, persistent cytopenias, and a history of infections. The Company has reported this serious adverse event and patient death to the FDA. The filing includes standard forward-looking statement disclaimers regarding the risks associated with clinical development timelines and regulatory approvals.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical breakdowns of the clinical trial.
- Review the Company's most recent Form 10-Q or 10-K for current financial liquidity and cash runway, as this 8-K does not contain financial data.
- Monitor upcoming presentations for mid-2021 longer-term follow-up data on PBCAR0191.
- Assess the impact of the reported patient death on the overall safety profile and regulatory strategy for PBCAR0191.
- Confirm the timeline for the initiation of clinical trials for the PBCAR19B candidate in 2021.